Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305809 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
NCT03305809 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 344 participants.
The verdict
NCT03305809, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
Study Summary
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
Interventions
- DRUG Placebo
- DRUG LY3154207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2020-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03305809
The ClinicalTrials.gov registry entry for NCT03305809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03305809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03305809 about?
NCT03305809 is a clinical study titled "A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)". A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
What is the current status of trial NCT03305809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2017-11-09. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT03305809?
The interventions under investigation include: Placebo (DRUG), LY3154207 (DRUG).
Who is sponsoring clinical trial NCT03305809?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.